The trial forms part of the Blood Biomarker Challenge, a multimillion-pound programme supported by Alzheimer’s Society, Alzheimer’s Research UK and the People’s Postcode Lottery. Experts believe blood tests such as plasma p-tau217 can detect these proteins as accurately as current – but more invasive – methods such as PET scans and lumbar punctures. The Alzheimer’s Disease Diagnosis and Plasma pTau217 (Adapt) team behind the study is led by Professor Jonathan Schott and Dr Ashvini Keshavan. The impact of blood test results on quality of life will also be measured. This team is assessing multiple new and existing blood tests, looking at a range of dementia types including Alzheimer’s disease, vascular dementia, frontotemporal dementia, and dementia with Lewy bodies.